Compare Extra Space Storage, Inc. (EXR) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Moderna, Inc. — how do they compare? Extra Space Storage, Inc. trades at $150.27 (market cap $30.56B), while Moderna, Inc. trades at $63 (market cap $27.09B). The key difference: Extra Space Storage, Inc. and Moderna, Inc. are close in size by market cap, and Extra Space Storage, Inc. pays a 4.48% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| EXR | MRNA | |
|---|---|---|
Market Cap | $30.56B | $27.09B |
Sector | Real Estate | Health |
52-Week High | $152.75 | $81.80 |
52-Week Low | $126.67 | $22.36 |
Enterprise Value | $44.36B | $23.19B |
Dividend Yield | 4.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXR trades at $148.89, up 2.33% over 24 hours, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.14 exceeding expectations. Revenue reached $3.38B in 2025, with a net income margin of 27.66%, though ROE remains modest at 6.92%. Recent news highlights steady expansion and a $550 million senior notes issuance, while analyst consensus is a $155.88 price target with a mix of Buy and Hold ratings.
Outlook is cautiously optimistic given consistent earnings performance and resilient demand, but risks include high debt levels, competitive pressures, and expense growth outpacing revenue. The stock's valuation metrics like P/E of 32.5 suggest it is priced for growth, yet investor sentiment is divided, with technical indicators showing neutral momentum near key support at $144.
Moderna (MRNA) trades at $64.11, down 4.94% over 24 hours, with a bullish technical outlook but mixed fundamentals. The company reported a net loss of -$2.82B in 2025 despite beating EPS estimates in recent quarters. Recent news highlights progress in oncology trials and an EU RSV vaccine contract, fueling investor optimism about pipeline expansion beyond COVID-19 vaccines.
Outlook: Long-term growth depends on successful pipeline commercialization, but high cash burn and negative margins pose risks. Analyst consensus is cautious with a $49 price target, suggesting 23.6% downside. Investors should weigh clinical successes against persistent profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
